SAN DIEGO, California ― For patients with moderate to severe rheumatoid arthritis whose condition is refractory to methotrexate, pain relief is better with the JAK inhibitor baricitinib than with the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Baricitinib preserved C-peptide levels and lowered ...

Please provide your email address to receive an email when new articles are posted on . Within the baricitinib group, patients experienced a mean Vitiligo Area Scoring Index score change of 44.8% from ...

Baricitinib can effectively treat polymyalgia rheumatica (PMR) without the use of oral glucocorticoids, according to results from a small, randomized, double-blind, placebo-controlled study. Among the ...

Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles. Breakdown of immune privilege in hair follicles leads to infiltration by ...

The effects of the JAK inhibitor baricitinib (Olumiant) waned after treatment was stopped among patients with new-onset type 1 diabetes, 2-year data from the phase II BANDIT trial showed. After ...

In an interview with Brittany Craiglow, MD, FAAD, dermatologist at Dermatology Physicians of Connecticut in Fairfield, she advocates for combination therapies using baricitinib to treat pediatric ...

Baricitinib displayed long-term effectiveness and safety in pediatric patients with atopic dermatitis (AD), recent study data show. The phase 3 study included 467 patients between ages 2 and 17. At ...

A pill typically prescribed for rheumatoid arthritis and alopecia might help slow the progression of type 1 diabetes, a new study says. Baricitinib safely preserved the body's own insulin production ...

A daily pill previously shown to slow the progression of type 1 diabetes has now shown a loss of therapeutic benefit when stopped—affirming the promise of the treatment. In 2023, an Australian trial ...

TUESDAY, March 18, 2025 (HealthDay News) -- For adolescents with severe alopecia areata (AA), baricitinib is efficacious for ...

At week 36, 42.4 and 27.4% of patients receiving baricitinib 4mg and baricitinib 2mg, respectively, achieved a SALT score of less than or equal to 20 compared with 4.5% of patients receiving placebo.